Aulos Bioscience Presents Poster on Phase 1/2 Clinical Trial of Computationally Designed IL-2 Antibody AU-007 at 2022 ASCO Annual Meeting
27 May 2022
ASCOClinical ResultCollaborateAntibodyImmunotherapy
LARKSPUR, Calif.--(BUSINESS WIRE)-- Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today shared a Trials in Progress poster that is being presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting. The poster showcases the study design for the company’s first-in-human Phase 1/2 trial of AU-007 that is currently enrolling patients in Australia. AU-007 is a human monoclonal antibody computationally designed by Biolojic Design, with a highly differentiated approach to harnessing the power of interleukin-2 (IL-2)IL-2) to eradicate solid tumors.
“AAU-007stands apart with a mechanism of action that is entirely different from every other IIL-2therapeutic in development,” said Aron Knickerbocker, AAulos Biosciences chief executive officer. “This Phase 1/2 study is the first time that a computationally designed human monoclonal antibody has been tested in humans. By addressing the IIL-2negative feedback loop, we believe AAU-007could potentially subdue immune suppression and prevent the toxic side effects of IIL-2 leading to a novel treatment for ssolid tumor cancers”
The Trials in Progress poster describes how AAU-007can bind human IIL-2with picomolar affinity and precisely block IIL-2s binding to CD25, without hindering IIL-2s binding to CCD132CCD122 Through this unique mechanism of action, AAU-007can transform the IIL-2negative feedback loop into a positive one, tipping the balance toward immune activation and away from immune suppression. Recently released preclinical data of murine models demonstrate that redirected IIL-2signaling by AAU-007can lead to significant ttumorgrowth inhibition, and complete MMC38 colorectal tumorelimination when AAU-007is dosed in combination with checkpoint inhibitors.
The company’s Phase 1/2 trial (NCT05267626) is a two-part, open label, first-in-human study evaluating the safety, tolerability, immunogenicity and clinical activity of AAU-007in patients with unresectable locally advanced or metastatic cancer. Phase 1 consists of three dose escalation arms evaluating AAU-007either as a monotherapy, in combination with a single loading dose of aaldesleukin or with both AAU-007and aaldesleukinadministered once every two weeks. The Phase 2 portion of the trial evaluates a dosing regimen selected from dose escalation for expansion in specified ttumortypes to further define the safety and initial efficacy of AAU-007 Dosing of patients commenced in May, and preliminary data from the Phase 1 portion of the clinical trial is expected by late 2022.
The Trials in Progress poster is available to meeting registrants as an e-poster on the ASCO Annual Meeting website and will be presented live in the Trials in Progress poster session “Developmental Therapeutics—Immunotherapy” on Sunday, June 5, 2022, 8:00 a.m. to 11:00 a.m. CDT.
About AAU-007
AAU-007is a computationally designed, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IIL-2 With a mechanism of action unlike any other IIL-2therapeutic in development, AAU-007leverages IIL-2to reinforce anti-ttumorimmune effects. This is achieved by preventing IIL-2 either exogenous or secreted by T effector cells, from binding to trimeric receptors on T regulatory cells while still allowing IIL-2to bind and expand T effector and NK cells. This prevents the negative feedback loop caused by other IIL-2based treatments and biases the immune system toward activation over suppression. AAU-007also prevents IIL-2from binding to trimeric receptors on vasculature and pulmonary endothelium, which may significantly reduce the vascular leak syndrome and ppulmonary edemaassociated with high-dose IIL-2therapy.
About AAulos
AAulos Bioscienceis an immuno-oncology company working to revolutionize ccancerpatient care through best-in-class IIL-2therapeutics that direct patients’ immune systems toward killing ttumorcells. Matching world-class machine learning from co-founder BBiolojic Designwith an in-depth understanding of the immune system, Aulos’ initial clinical candidate, AAU-007 is a computationally designed human antibody that harnesses the power of IIL-2to induce ttumorkilling while limiting the immunosuppression and toxicities typically associated with this validated pathway. The company was founded by BBiolojic Designand ATP with $40 million in Series A funding from ATP and is led by pioneers in the field of artificial intelligence, antibody development and ccancerimmunotherapies. For more information, visit www.aulosbio.com.<br>
Organizations
Indications
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.